The Wistar Institute of Anatomy & Biology

DUBLIN--( BUSINESS WIRE )--The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering. Since NGS platforms can sequence an entire genomic region or even an entire genome, a single test can examine hundreds or thousands of clinically important genetic variations. This means that one test can replace multiple conventional single-gene tests, providing an advantage in price and in the amount of precious sample needed for the test itself. NGS is often more accurate and reliable than existing diagnostics. This can result in better clinical outcomes. For example, NGS can increase the pregnancy success rates in in vitro fertilization applications. Also, in rare genetic diseases, NGS can increase the success rates for determining a molecular diagnosis. The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test. This strategy has been employed in reproductive health applications, for example, launching a test to initially screen for aneuploidies, and then later expanding the test to include screening for additional genetic variants. These features of NGS platforms provide a solid basis for the use of this technology in the clinic. The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies. The markets for NGS-based diagnostics are given for the years 2020, 2021, 2022, 2023 and 2028. This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. Liquid biopsy formats are discussed. The main market driving forces are also discussed. The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future. The report provides market data and forecasts for NGS diagnostics by specific applications, including those for oncology, cardiovascular diseases, clinical microbiology/infectious diseases, Mendelian disorders, metabolic/immune disorders, neurological disorders, reproductive health, and transplant medicine. Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct-to-consumer testing; and noninvasive prenatal testing. More than 100 companies in the clinical NGS industry are profiled in this report. The Report Includes 41 data tables and 237 additional tables An overview of the global market for emerging clinical applications of next-generation sequencing Analysis of global market trends, featuring historical revenue data for 2020 to 2022, estimates for 2023, as well as forecasts for 2028, including projections of compound annual growth rates (CAGRs) through 2028 Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by disease indication, test complexity, test purpose, application and geographic region Discussion of market opportunities for clinical NGS products, clinical applications, industry structure, regulatory scenarios and use of NGS-based diagnostics and technologies Coverage of genome mapping programs, technological advances and innovations in NGS platforms, and the Ion Torrent Genexus System from Thermo Fisher Scientific and the Magnis NGS Prep System from Agilent Technologies Inc Description of NGS-oriented tests such as non-invasive prenatal testing (NIPT) and pre-implantation genetic testing (PGT), and a discussion of their advantages Market share analysis of the key companies and a look at their proprietary technologies, strategic alliances and other key market strategies, plus a patent analysis Profiles of the leading players, including Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN, Agilent Technologies Inc., and BGI Genomics Key Attributes: Report Attribute Details No. of Pages 492 Forecast Period 2023 - 2028 Estimated Market Value (USD) in 2023 $21.9 Billion Forecasted Market Value (USD) by 2028 $52.9 Billion Compound Annual Growth Rate 19.3% Regions Covered Global Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Overview Liquid and Tissue Biopsy Clinical NGS Market Growth Drivers of Clinical NGS Key Trends Industry Chapter 4 Technology Background Importance of DNA Genetic Variation and Analysis Genetic Analysis Technologies Sequencing in Clinical Applications Sequencing Technologies History of DNA Sequencing Sanger Sequencing Technology NGS Platforms Short-Read Platforms Long-Read Platforms Informatics Technologies Base Calling Mapping to a Reference Sequence Variant Analysis Artificial Intelligence Technologies Clinical Sequencing Technology Challenges Chapter 5 Clinical NGS Initiatives and Emerging Technologies R&D Initiatives and Programs 1+ Million Genomes Access to Treatment and Testing (ACTT) Access to Comprehensive Genomic Profiling Coalition (ACGP) Africa Pathogen Genomics Initiative Blood Profiling Atlas Cancer-ID Cancer Moon Shots Program China Precision Medicine Initiative ClinGen CTC Trap Consortium diaRNAgnosis Project Early Cancer Detection Consortium EpiFemCare France Genomic Medicine Plan Friends of Cancer Research Project Genomic Medicine Sweden HCA-Organoid Human Cell Atlas Human Immunomics Initiative Immunomonitor Consortium Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program Intervene Liquid Biopsies and Imaging for Improved Cancer Care Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project Liver Cancer Early Screening Comprehensive Prevention and Control Project Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Million Veteran Program Medical Genome Initiative MedSeq Precision Medicine Initiative Prompt QuIP Project SPHERES Target ALS Diagnosis Initiative TopMed Treehouse Childhood Cancer Initiative Very Rare Cancer Consortium Worldwide Innovative Networking (WIN) Consortium Single-Cell Research Cambridge Single-Cell Analysis Core Facility Harvard Medical School Single-Cell Core Mayo Medical Genome Facility National Center for Single-Cell Biology Next-Generation Single-Cell Analysis Program Single-Cell Analysis Core UC San Francisco Single-Cell Analysis Center The Wistar Institute of Anatomy and Biology Population Sequencing Projects Chapter 6 Clinical NGS Applications Chapter 7 Clinical NGS Industry Chapter 8 ESG Development Chapter 9 Acquisitions and Strategic Alliances Chapter 10 Clinical NGS Markets Chapter 11 Patent Review Chapter 12 Company Profiles Agilent Technologies Inc. Bgi Genomics Co. Ltd Illumina Inc. Qiagen Thermo Fisher Scientific Inc. Accuragen Holdings Adaptive Biotechnologies Alcen Ambry Genetics Amoy Diagnostics Co. Ltd. Angle Plc Apostle Sciences Arcedi Biotech Aps Armonica Technologies Inc. Arup Laboratories Asuragen Inc. Baylor Genetics Becton, Dickinson And Co. Berry Genomics Beijing Biocaptiva Ltd. Biocept Inc. Biodesix Biofluidica Biolidics Ltd Biological Dynamics Biomodal Bionano Genomics Bio-Rad Laboratories Inc. Bio-Techne C2I Genomics Capio Biosciences Caredx Inc. Caris Life Science Cegat Gmbh Cell Microsystems Centrillion Genomics Technologies Claret Bioscience Clear Note Health Clinical Genomics Technologies Cyclomics Cygnus Biosciences Co. Ltd. Danaher Dante Labs Datar Cancer Genetics Ltd. Delfi Diagnostics Diacarta Diagnologix Llc Diagnomics Inc. Diamir Bio Dnalytics Dnanexus Inc. Earlydiagnostics Epic Sciences Epigenomics Ag Eurofins Genomics Everly Health Inc. Exact Sciences Corp. Exopert Exosomics Inc. Ezlife Bio Fabric Genomics Inc. F. Hoffmann-La Roche Ltd Fluxion Biosciences Inc. Freenome Holdings Inc. Fulgent Genetics Full Genomes Corp. Gene By Gene Ltd. Genedx Llc Geneseq Biosciences Genomoncology Llc Genosaber Grail Inc. Guardant Health Helio Genomics Helix Inc. Htg Molecular Diagnostics Inc. Imagia Canexia Health Incelldx Inc. Inex Innovate Private Ltd Inoviq Interpace Biosciences Inc. Invitae Corp. Invivoscribe Inc. Jabrehoo Med Tech Co. Ltd. Jbs Science Jumpcode Genomics Koninklijke Philips Labgenomics Lucence Health Macrogen Mapmygenome Mdxhealth Inc. Medgenome Medicover Genetics Merck Kgaa Micareo Rare Cell Diagnostics Micronoma Inc. Mir Scientific Mutantdx Myriad Genetics Inc. Nanostring Technologies Inc. Natera Inc. Nebula Genomics Neogenomics Laboratories New England Biolabs New Horizon Health Ltd. Novigenix Novogene Co. Ltd. Nrichdx Inc. Nuprobe Inc. Nx Prenatal Inc. Oncimmune Holdings Plc Oncocyte Corp. Oncodna Opko Health Orchid Oxford Nanopore Technologies Ltd. Pangaea Oncology Personal Genome Diagnostics Inc. Personalis Inc. Phase Scientific Pieriandx Predicine Prenetics Group Qcdx Llc Quantapore Quantgene Inc. Quantumdx Quest Diagnostics Rarecells Inc. Ravgen Real Time Genomics Resolution Bioscience Inc. Saga Diagnostics Sano Genetics Screencell Seekin Inc. Sequencing.Com Seven Bridges Genomics Inc. Single Technologies Smartcatch Strand Strata Oncology Syapse Inc. Sysmex Inostics Takara Bio Inc. Telexos Gmbh Twinstrand Biosciences Inc. Twist Bioscience Unchained Labs Universal Dx Vela Diagnostics Veracyte Volitionrx Vortex Biosciences Yourgene Health Yikon Genomics For more information about this report visit https://www.researchandmarkets.com/r/tklgxp About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

The zebrafish serves as a model organism for researchers around the world: it can be used to study important physiological processes that also take place in a similar form in the human body. It is therefore routinely used in the search for possible active substances against diseases. Researchers have now described an innovative way to do this. In this process, the larvae fish are made a bit more 'human-like'. This humanization could make the search for active pharmaceutical substances much more efficient. The zebrafish should be known to many aquarium enthusiasts mainly because of its striking pigmentation. However, the characteristic black-blue stripes, to which the animal owes its name, only form over time. Its eyelash-sized larvae, on the other hand, are still more or less transparent. Many developmental processes in their bodies can therefore be observed under the light microscope. For this reason, they now serve as a model organism for research groups around the globe. "At the University of Bonn, for example, we are investigating how zebrafish repair defective nerve tissue," explains Prof. Dr. Benjamin Odermatt from the Institute of Anatomy at the University Hospital Bonn. "We are also interested in this because many genes involved in this process also exist in a similar form in humans." In principle, agents that boost these repair genes in fish could thus also work in humans. However, the differences between the genetic makeup of fish and humans are often significant. The larvae are therefore sometimes of limited use in the search for new drugs. Fish gene replaced by human gene "We therefore took a different approach," explains Prof. Dr. Evi Kostenis from the Institute of Pharmaceutical Biology at the University of Bonn. " For a human gene known to play a role in the repair of nerve cells we looked for its counterpart in zebrafish. Then we excised this counterpart in the fish and replaced it with the human version." The new genetic material took over the function of the original zebrafish gene. "If we now find a substance that boosts the repair processes in the fish with the human gene, there is a good chance that this will also be the case in humans," says the scientist, who is also a member of the Transdisciplinary Research Area "Life and Health" at the University of Bonn. The researchers demonstrated that this replacement works in their pilot study on the so-called GPR17 receptor. In humans, its overactivation can lead to diseases such as multiple sclerosis (MS). Nerve cells communicate by means of electrical signals. Their extensions are surrounded by a kind of insulating layer, a lipid-like substance called myelin. It prevents short circuits and also significantly speeds up the transmission of stimuli. This protective sheath is produced by specialized cells named oligodendrocytes. These resemble a microscopic octopus: many long arms extend from their cell body, most of which consist of myelin. Like an insulating tape, these wrap themselves around the nerve cell processes during brain development. Normally, the protective layer lasts a lifetime. Insulating tape dispenser remain in immature state In multiple sclerosis, however, the body's own immune system destroys the myelin layer. This results in neurological disorders, for example in speech, vision or walking. But normally there is a supply of immature oligodendrocytes in the brain for repair work. When damage occurs, they mature and patch up the hole. In multiple sclerosis, this mechanism is disrupted -- many of the cellular insulating tape donor cells remain in their immature state. The GPR17 receptor seems to bear the main blame for this: if it is activated by a molecular signal, it slows down the maturation of the oligodendrocytes. "Zebrafish also have a GPR17 receptor," explains Dr. Jesus Gomeza, who led the study with Kostenis and Odermatt. "And there it also regulates how many oligodendrocytes mature." The researchers now replaced part of the receptor gene with its human counterpart -- namely, the very structure responsible for receiving molecular signals. "We were able to show that this new mosaic gene functions normally in the fish larvae," says Gomeza. A molecule that inhibits the human GPR17 receptor in the test tube also cranked up the formation of mature oligodendrocytes in the modified fish. In the search for new active ingredients, substances are first tested in cell cultures. Only individual, very promising candidates are then tested in mice or other animal models. But even if they work there, tests in humans still often end soberingly. "Humanized zebrafish larvae allow many substances to be screened quickly, and with a high chance of success, since the target genes originate from humans," explains Benjamin Odermatt. "From our point of view, this is a very promising avenue for drug development."

Chronic diseases often lead to fibrosis, a condition in which organ tissue suffers from excessive scarring. Researchers have now developed an immunotherapy that specifically targets the cause -- activated fibroblasts -- while leaving normal connective tissue cells unharmed. If this approach is also found to work in humans, it could lead to an effective treatment for fibrosis. Fibrosis is a pathological proliferation of connective tissue that destroys the organ tissue. It is the ultimate consequence of almost every kind of chronic damage. Fibrosis can occur in almost every type of tissue in the body, although the liver, lungs, heart and kidneys are most often affected. Fibrosis is responsible for up to 45 percent of all mortality in industrialized countries. Inflammation or vascular disorders often cause chronic organ damage. They activate the fibroblasts, which then begin to proliferate uncontrollably and create deposits of fibrous tissue. This scars the organ tissue, destroying it little by little. The functioning of the affected organ worsens noticeably until it fails completely. Eliminating activated fibroblasts while leaving resting cells undamaged An international research team led by the University of Zurich (UZH) has now developed a new strategy to eliminate fibroblasts in a targeted manner. "In animals, we were able to trigger an immune response similar to that to a vaccination, in which the activated connective tissue cells were destroyed while the resting fibroblasts were left unharmed," explains study leader Professor Christian Stockmann of the Institute of Anatomy at the University of Zurich. In this manner, researchers were able to reduce fibrosis in vital organs such as liver and lungs while at the same time leaving healthy tissue unharmed. Difference in surface structures identified This is where previous strategies for fibrosis treatment had previously failed, since they also damaged resting fibroblasts. Resting fibroblasts are important, however, for maintaining the structure and functioning of healthy tissue. Researchers therefore studied the differences between the surfaces of resting and of activated connective tissue cells. "Our computer-assisted analyses revealed that fragments of two surface proteins -- Adam12 and Gli1 -- which can be detected by the immune system, are present in large numbers on activated fibroblasts, while there are very few on the resting cells," explains Stockmann. The activity of these two protein genes is stimulated by chronic tissue damage, which means the activated fibroblasts produce the said proteins in larger quantities. Immunotherapy reduces lung and liver fibrosis in mice The researchers then used these two surface structures as a vaccine in mice in order to trigger an immune response via cytotoxic T-cells. These immune cells normally eliminate virus-infected or cancerous cells. "With the newly developed immunotherapy, we were able to eliminate fibroblasts efficiently in mice, thus reducing fibrosis in the liver and the lungs, without affecting healthy organ tissue," says Stockmann. If scientists manage to successfully trigger a comparable, targeted immune response in humans, then vaccine-based immunotherapy could be used in future for the treatment of patients with organ fibrosis.